Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.

Amgen Inc. has found a way to help US patients with high-risk cardiovascular disease who are covered by Medicare Part D plans spend the same amount of money out of their own pockets for Repatha (evolocumab) as patients covered by commercial plans.

Because Medicare Part D co-payments are based on Repatha's current list price of $14,523, those individuals may pay as much as $370 per dose of the cholesterol-lowering PCSK9 inhibitor. As a result, about 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon Repatha at the pharmacy counter. To reduce the abandonment rate, Amgen said on Oct

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

15 May 2025

• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

AbbVie On MFN: ‘We Have To Take It Seriously’

14 May 2025

• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.